Bradley Sitko Purchases 4,134 Shares of XOMA Co. (NASDAQ:XOMA) Stock

XOMA Co. (NASDAQ:XOMA) CIO Bradley Sitko acquired 4,134 shares of the business’s stock in a transaction on Friday, March 21st. The stock was acquired at an average price of $23.89 per share, for a total transaction of $98,761.26. Following the acquisition, the executive now owns 10,484 shares of the company’s stock, valued at approximately $250,462.76. This trade represents a 65.10 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Bradley Sitko also recently made the following trade(s):

• On Wednesday, January 8th, Bradley Sitko purchased 313 shares of XOMA stock. The stock was bought at an average cost of $25.60 per share, for a total transaction of $8,012.80.
• On Tuesday, December 31st, Bradley Sitko acquired 300 shares of XOMA stock. The shares were bought at an average cost of $25.90 per share, with a total value of $7,770.00.

XOMA Stock Down 0.9 %

XOMA stock traded down $0.19 during midday trading on Tuesday, hitting $20.74. The company’s stock had a trading volume of 29,881 shares, compared to its average volume of 26,515. The firm’s 50-day moving average is $24.28 and its 200-day moving average is $27.08. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. XOMA Co. has a 12 month low of $19.92 and a 12 month high of $35.00. The company has a market cap of $248.44 million, a PE ratio of -5.96 and a beta of 1.00.

XOMA (NASDAQ:XOMA) last announced its quarterly earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.17). XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. The business had revenue of $8.70 million for the quarter, compared to the consensus estimate of $8.75 million. On average, equities research analysts forecast that XOMA Co. will post -1.41 earnings per share for the current fiscal year.

Institutional Trading of XOMA

A number of institutional investors have recently made changes to their positions in XOMA. Woodline Partners LP boosted its holdings in XOMA by 63.9% in the fourth quarter. Woodline Partners LP now owns 156,266 shares of the biotechnology company’s stock worth $4,107,000 after purchasing an additional 60,927 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of XOMA by 238.9% during the 4th quarter. JPMorgan Chase & Co. now owns 12,089 shares of the biotechnology company’s stock valued at $318,000 after buying an additional 8,522 shares during the period. Barclays PLC boosted its stake in shares of XOMA by 300.7% in the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after buying an additional 8,447 shares during the last quarter. Los Angeles Capital Management LLC bought a new stake in shares of XOMA in the fourth quarter worth $206,000. Finally, Renaissance Technologies LLC increased its position in XOMA by 89.8% during the fourth quarter. Renaissance Technologies LLC now owns 16,100 shares of the biotechnology company’s stock valued at $423,000 after acquiring an additional 7,619 shares during the last quarter. Hedge funds and other institutional investors own 95.92% of the company’s stock.

Wall Street Analysts Forecast Growth

XOMA has been the topic of a number of recent research reports. HC Wainwright reissued a “buy” rating and issued a $104.00 target price on shares of XOMA in a research note on Wednesday, March 19th. StockNews.com raised shares of XOMA from a “sell” rating to a “hold” rating in a research report on Friday.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.